Abstract
BackgroundIn large multiregional cohort studies, survival data is often collected at small geographical levels (such as counties) and aggregated at larger levels, leading to correlated patterns that are associated with location. Traditional studies typically analyze such data globally or locally by region, often neglecting the spatial information inherent in the data, which can introduce bias in effect estimates and potentially reduce statistical power.MethodWe propose a Geographically Weighted Accelerated Failure Time Model for spatial survival data to investigate spatial heterogeneity. We establish a weighting scheme and bandwidth selection based on quasi-likelihood information criteria. Theoretical properties of the proposed estimators are thoroughly examined. To demonstrate the efficacy of the model in various scenarios, we conduct a simulation study with different sample sizes and adherence to the proportional hazards assumption or not. Additionally, we apply the proposed method to analyze ovarian cancer survival data from the Surveillance, Epidemiology, and End Results cancer registry in the state of New Jersey.ResultsOur simulation results indicate that the proposed model exhibits superior performance in terms of four measurements compared to existing methods, including the geographically weighted Cox model, when the proportional hazards assumption is violated. Furthermore, in scenarios where the sample size per location is 20-25, the simulation data failed to fit the local model, while our proposed model still demonstrates satisfactory performance. In the empirical study, we identify clear spatial variations in the effects of all three covariates.ConclusionOur proposed model offers a novel approach to exploring spatial heterogeneity of survival data compared to global and local models, providing an alternative to geographically weighted Cox regression when the proportional hazards assumption is not met. It addresses the issue of certain counties' survival data being unable to fit the model due to limited samples, particularly in the context of rare diseases.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.